Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lorcaserin Clear all
Completed No phase listed Observational Accepts healthy volunteers

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

NCT03552107
View directory record Official record
Conditions
Obesity, Weight Loss, Overweight
Interventions
Lorcaserin
Drug
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 24, 2026, 11:50 AM EDT
Terminated Early Phase 1 Interventional Results available

Lorcaserin for Cannabis Use Disorder

NCT03637842
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Lorcaserin, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 24, 2026, 11:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

NCT02523690
View directory record Official record
Conditions
Muscle Weakness, Sepsis
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 24, 2026, 11:50 AM EDT
Completed No phase listed Observational Results available

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

NCT03143855
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence, Opioid-Related Disorders, Opioid Use
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 24, 2026, 11:50 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Lorcaserin Intra Venous Cocaine Effects

NCT02680288
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
Lorcaserin, 10 mg, Lorcaserin, 20 mg, Oral Placebo
Drug · Other
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
21 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

NCT03169816
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 24, 2026, 11:50 AM EDT
Terminated Phase 1 Interventional

Gene-by-Stress Interactions in Intervention Studies Significance

NCT03011645
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Ziprasidone, Lorcaserin, Placebo Oral Tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 24, 2026, 11:50 AM EDT
Withdrawn Phase 1 Interventional

Rebalancing the Serotonergic System in Cocaine Dependence

NCT03266939
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Lorcaserin, Placebo Oral Tablet
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin for Preventing Weight Gain Among Smokers

NCT02393547
View directory record Official record
Conditions
Tobacco Use Disorder, Weight Gain
Interventions
Varenicline, Lorcaserin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

NCT00828581
View directory record Official record
Conditions
Obesity
Interventions
lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

NCT00828438
View directory record Official record
Conditions
Renal Impairment
Interventions
Lorcaserin 10mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 1 Interventional

Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder

NCT02932215
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
lorcaserin, Fitbit Charge HR
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

NCT00828932
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin in the Treatment of Cocaine Use Disorder

NCT03007394
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Lorcaserin, Placebo Oral Capsule
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 24, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Results available

Treatment With Lorcaserin for Cocaine Use: The TLC Study

NCT03192995
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
lorcaserin, Placebo Oral Tablet, Substance use counseling, ACASI, Cocaine metabolites, Ecological Momentary Assessment (EMA), Balloon Analogue Risk Task (BART), Qualitative Exit Interview
Drug · Behavioral · Diagnostic Test
Lead sponsor
Glenn-Milo Santos
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 24, 2026, 11:50 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

NCT04572243
View directory record Official record
Conditions
Epilepsies, Myoclonic
Interventions
Placebo, Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 24, 2026, 11:50 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Predictors of Lorcaserin-Induced Weight Loss

NCT03353220
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Belviq, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 24, 2026, 11:50 AM EDT
Not listed Phase 2 Interventional

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT03812523
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy
Interventions
Duloxetine 60 mg qd, Lorcaserin
Drug
Lead sponsor
Southeastern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

NCT02388568
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

NCT02129608
View directory record Official record
Conditions
Overweight, Obese
Interventions
LLLT, Lorcaserin
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 4 Interventional Results available

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

NCT01987427
View directory record Official record
Conditions
Chronic Weight Management
Interventions
lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 24, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

NCT00395135
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg BID, Matching Placebo BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 24, 2026, 11:50 AM EDT